> Serono has signed a development and commercialization pact with Syntonix Pharmaceuticals for its FSH:Fc candidates to treat infertility. Syntonix gains a collaboration fee and will stand to earn up to $54 million in milestones if Serono exercises its option in the deal. Report
> You can add the name of Sanofi-Aventis to the growing list of potential suitors for Bristol-Myers Squibb. Article
> GlaxoSmithKline has filed for U.S. approval of Tykerb in combination with Xeloda for the treatment of advanced or metastatic HER2 (ErbB2) positive breast cancer in women who have received prior therapy. Release
> Tenby Pharma, a shell company, has acquired Sirion Therapeutics and arranged $25 million in financing. Report
> Opexa Therapeutics is reporting positive data for its Phase I/II trial of the MS drug Tovaxin. The drug developer has also announced the launching of its 150-patient Phase IIb Tovaxin trial. Release
> The European Commission has granted orphan medicinal status to Nektar Therapeutics' Amphotericin B Inhalation Powder. Release
> Schering has granted an exclusive worldwide license to Bausch & Lomb to develop and market a selective glucocorticoid receptor agonist for the non-systemic treatment of eye disorders. Release
> The World Bank estimates that a bird flu pandemic could cost between $1 trillion and $2 trillion, or about three percent of global GNP. Report
> Chutes & Ladders: Targanta Therapeutics has named Mark Leuchtenberger as the company's new president and CEO. Release
And Finally… New research indicates that 40 percent of the people who get botoxed become addicted to the cosmetic procedure that paralyzes facial muscles. Report